Becton, Dickinson and Company BDX, popularly known as BD, recently announced that it has applied for CE Mark approval for its Liverty TIPS Stent Graft to advance treatment options for portal hypertension across the European Union. The next-generation device, featuring an adjustable-diameter design, is intended to support patients with cirrhosis and related complications of portal hypertension.
Per management, expanding access to reliable and adaptable treatment options is essential for patients facing complications of portal hypertension. With the CE Marking of the Liverty TIPS Stent Graft, BD aims to deliver an innovative, adjustable solution that enables physicians to personalize therapies and enhance the potential for improved long-term patient outcomes.
Likely Trend of BDX Stock Following the News
Following the announcement, BDX shares gained 1.4% at yesterday’s closing. In the year-to-date period, shares of the company lost 19.1% compared with the industry’s 3.3% decline and the S&P 500’s 3.6% fall.
In the long run, the CE Mark approval of the Liverty TIPS Stent Graft will provide BD with a commercial foothold in Europe and strengthen its competitive positioning in interventional therapies for liver disease. As the burden of liver disease and portal hypertension continues to rise globally, this innovation underscores BD’s commitment to advancing interventional therapies and expanding treatment options for patients with complex liver disease, improving both procedural success and quality of life.
BDX currently has a market capitalization of $44.12 billion.
Image Source: Zacks Investment Research
More on the News
Cirrhosis continues to pose a major global health burden, affecting an estimated 58 million people worldwide. The condition often leads to portal hypertension, which can cause severe complications such as variceal bleeding and fluid accumulation in the abdomen or chest. Procedures like Transjugular Intrahepatic Portosystemic Shunt (TIPS) are helpful in managing these complications by reducing portal pressure and improving blood flow.
BD’s Liverty TIPS Stent Graft introduces a next-generation, patient-centric design aimed at improving procedural precision and long-term outcomes. The device features an adjustable inner diameter ranging from 6 to 10 mm, allowing physicians to tailor treatment based on individual patient needs. It offers a broad range of stent lengths, enhancing flexibility in complex anatomical cases.
The stent graft is built with a flexible self-expanding nitinol frame and dual-layer ePTFE encapsulation, including carbon impregnation on the inner surface to support durability and performance. It is delivered through a triaxial system engineered to provide enhanced placement accuracy, control and ease of use during procedures.
Clinical validation is underway, with safety and effectiveness data from the pivotal ARCH trial set to be presented by Global Principal Investigator Prof. Ziv Haskal, MD, at the Society of Interventional Radiology Annual Scientific Meeting 2026 on April 12, 2026. This will mark the first public disclosure of outcomes associated with the device.
Industry Prospects Favoring the Market
Going by the data provided by Market Research Intellect, the Transjugular Intrahepatic Portosystemic Shunt market is expected to witness a CAGR of 6.1% through 2033. Factors like the increasing prevalence of liver cirrhosis, advancements in minimally invasive medical procedures, innovations in shunt material and stent technology and rising demand for effective portal hypertension management are boosting the market’s growth.
Other News
BD recently announced that it has received CE Mark approval in the European Union for its Revello Vascular Covered Stent. This next-generation endovascular device is intended for treating atherosclerotic lesions in the common and external iliac arteries.
With this approval, BD is expanding its peripheral vascular portfolio and strengthening its presence in the growing peripheral artery disease treatment market.
Becton, Dickinson and Company Price
Becton, Dickinson and Company price | Becton, Dickinson and Company Quote
BDX’s Zacks Rank & Key Picks
Currently, BDX carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Pacific Biosciences of California PACB, Phibro Animal Health PAHC and GE HealthCare Technologies GEHC.
Pacific Biosciences of California, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted loss of 12 cents per share, which surpassed the Zacks Consensus Estimate by 36.8%. Revenues of $44.6 million beat the Zacks Consensus Estimate by 9.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PACB has an estimated earnings recession rate of 1.9% compared with the industry’s 14.1% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.7%.
Phibro Animal Health, currently carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
GE HealthCare Technologies, currently carrying a Zacks Rank #2, reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.
GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.
Free Report: Profiting from the 2nd Wave of AI Explosion
The next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.
Investors who bought shares like Nvidia at the right time have had a shot at huge gains.
But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.
Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.
Access AI Boom 2.0 now, absolutely free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Becton, Dickinson and Company (BDX): Free Stock Analysis Report
Pacific Biosciences of California, Inc. (PACB): Free Stock Analysis Report
Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report
GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).